December 16, 2020
Date: Dec 16, 2020
Duration: 20 Min
Sponsored by WuXi Advanced Therapies
This webcast features: Yiyu Dong, Head of Cell Line Development, and
David Barnard, Senior Scientist, Process and Technology Development, WuXi Advanced Therapies
The field of gene therapy has experienced significant growth in recent years. Adenoassociated virus (AAV)–mediated therapies account for ~70% of the gene therapy market. However, the manufacturing capacity for AAV vectors remains a critical bottleneck. WuXi Advanced Therapies launched a world-class AAV suspension platform early 2020. In this webinar, we will reveal the improvements that increased viral vector titer and yield on our platform.
The advancements in the platform include:
Significant increase of viral vector titer
Increased coverage of AAV serotypes
Decreased process variability by using chemically defined growth medium
Optimized and simplified downstream processing
An increase in integrated testing capacity.
Just fill out the form below to watch the recorded webcast now.
You May Also Like
